Drug Profile
APD 916
Alternative Names: APD916Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Class
- Mechanism of Action Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Cataplexy; Narcolepsy
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 13 Jul 2011 Suspended - Phase-I for Cataplexy in USA (PO)
- 13 Jul 2011 Suspended - Phase-I for Narcolepsy in USA (PO)